Novo Nordisk's Australian Tablet Race Tightens as CagriSema Data and Buybacks Build the Case
Published on 11/17/2026 at 11:02 | Editorial boerse-global.deNovo Nordisk has secured approval for its Wegovy tablet in Australia, but the regulatory green light may not translate into first-mover advantage. Rival Eli Lilly's Foundayo has now cleared the country's Therapeutic Goods Administration, according to a report from Australian broadcaster Nine, and is expected on shelves within days — well ahead of Wegovy's stated availability of late 2026.
That timing gap is the crux for investors. Novo holds approval but has guided only to a year-end delivery window, while Lilly is preparing near-term shipments. The distinction shifts attention from regulatory milestones to the harder work of commercial execution.
Foundayo's Australian clearance covers both weight management and type 2 diabetes. Its reported monthly price runs AUD 250–370 depending on dose. The Wegovy tablet carries a recommended monthly price of AUD 260–395, according to the Australian Financial Review — a list-price recommendation rather than a measure of realised sales.
Self-Pay Market Shapes the Contest
Reimbursement dynamics add another layer. Australia's PBS generally does not subsidise GLP-1 medicines prescribed solely for weight loss, and both tablets are prescription-only. With patients largely paying out of pocket, price becomes a central competitive lever.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Dosing convenience also differs. Foundayo can be taken at any time of day; the Wegovy tablet must be taken in the morning on an empty stomach. Neither detail guarantees commercial success, though both form part of the concrete differences between the two products.
CagriSema's Phase 3 Readout
Behind the tablet battle, Novo's next-generation obesity candidate is advancing. The company reported positive primary results from the Phase 3 REDEFINE 9 trial of CagriSema, its investigational GLP-1 and amylin combination. Across 68 weeks of treatment, the two lower-dose groups achieved estimated average weight loss of 20.7% and 21.0%, against 2.0% for placebo.
Additional analyses of the REDEFINE 1 study, presented at ObesityWeek, showed that participants who responded early to CagriSema went on to lose an average of 25.4% of body weight after 68 weeks, according to the company.
CagriSema is positioned as a successor to Wegovy. Novo expects a US Food and Drug Administration decision on the drug for weight control in the fourth quarter of 2026, with a US launch planned for early 2027, subject to approval. The ObesityWeek data provide clinical context for that filing but do not substitute for the regulatory verdict or the commercial rollout that would follow.
Capital Returns and a Broader Pipeline
Alongside its clinical work, Novo has been buying back stock. The company repurchased roughly 43.7 million B shares for about DKK 12.1 billion under its programme, with the transactions reported as completed.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Novo also committed USD 200 million to the World Diabetes Foundation on 11 November. The pledge, aimed at a foundation, covers both prevention and treatment, and is intended to support diabetes prevention and care in low- and middle-income countries between 2027 and 2036.
Regulatory progress extends beyond obesity. The company announced EU approval for FREHEMGO for routine prevention of bleeding episodes in adults and children with haemophilia A. It has also filed applications with the FDA and the European Medicines Agency for Etavopivat in adolescents and adults with sickle cell disease.
For shareholders, the picture splits cleanly: in Australia, approval is banked and the next tests are availability, pricing and access; for CagriSema, the FDA decision remains the gate. Those two milestones — the Australian rollout and the US verdict — are the concrete markers ahead as Novo builds out its weight-management franchise.
Ad
Novo Nordisk Stock: New Analysis - 17 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
